Top Health Tech Companies With Best Stability & Growth (10,000+)

Strong Revenue Growth: Revenue is reported as expanding rapidly, with more than 60% year-over-year growth in committed ARR in 2024. External recognitions like Deloitte Technology Fast 500 and repeat Inc. 5000 placements point to sustained multi-year momentum.

Market Expansion: New health plan partnerships and an increase to 17 health plans by 2026, alongside 12 million annual prior authorizations and 25M covered lives, indicate a widening commercial footprint. Integrations such as Epic’s Payer Platform and expanded relationships with national and regional plans reinforce adoption.

Investor Backing & Capital Strength: A $90 million Series C in 2025 brought total funding to roughly $200 million. Successive raises and participation from prominent investors suggest ample capital to support scaling.

Strong Revenue Growth: Revenue increased 19% in 2025 and accelerated in 2026 with 22% year-over-year growth in Q1 and 27% in Q2, while first-half 2026 revenue rose 25% year over year. Management raised full-year 2026 guidance to $94–96M, implying roughly 22–24% growth.

Customer Loyalty & Retention: Net Dollar Retention reached 117% in Q1 2026, indicating expanding spend from existing accounts after churn. Core genomics customers rose to 537 as of March 31, 2026, with record new customer additions in 2025.

Market Expansion: Geographic momentum is evident with Q1 2026 analysis volume up 28% in the U.S. and 31% in APAC, and EMEA revenue up 30%. Platform usage set records (e.g., 108,000 analyses in Q1 and 115,000 in Q2), with liquid biopsy volumes growing sharply.

Strong Revenue Growth: Reported $100M in contracted annual recurring revenue by the end of 2025 and a high placement on Deloitte’s Technology Fast 500 together indicate substantial multi‑year expansion.

Investor Backing & Capital Strength: A $65M growth investment led by established firms signals strong access to capital and confidence in the company’s expansion plans.

Strong Market Position & Advantage: Recognition as #1 Best in KLAS for Patient Communications in 2026 and adoption across 1,000+ healthcare organizations reflect meaningful category standing.

Customer Loyalty & Retention: Autoship accounts for the vast majority of sales (over four-fifths) and is growing faster than total revenue, indicating a sticky, recurring base and higher retention. Evidence includes Autoship representing ~83% of FY2025 net sales and ~84.6% in Q2 FY2026 with high single‑digit to double‑digit growth.

Profitability: Operating metrics show expanding earnings power, with adjusted EBITDA up materially and margins improving alongside strong free cash flow. Observations include FY2025 adjusted EBITDA growth of ~26% with margin expansion and additional year‑over‑year gains reported in 1H FY2026.

Strong Market Position & Advantage: Chewy is characterized as the largest U.S. pet e‑tailer and a leading online pet‑supplies platform by GMV and digital presence, underpinning durable scale advantages. Multiple summaries highlight leadership in online pet retail, substantial Autoship penetration, and strong digital search share versus specialty peers.

Profitability: Company materials describe sustained annual profitability since 2023 and cash-flow positivity, pairing growth with disciplined financial health. It also reports meeting efficiency benchmarks, noting it exceeded the Rule of 40 in 2025.

Strong Revenue Growth: Disclosures point to multi-year revenue expansion with momentum described as accelerating, indicating robust top-line performance. This growth is presented alongside expanding provider and patient scale.

Strategic Partnerships: The platform is increasingly embedded across external channels through integrations with Healthgrades, Yelp, Google Gemini, and payer portals, broadening distribution and demand capture. These arrangements signal deeper ecosystem reach beyond the core marketplace.

Strong Revenue Growth: Available disclosures indicate revenue grew at a triple‑digit rate year over year in early 2026 and was later described as roughly $200M after multiple years of doubling. These signals point to rapid scaling beyond a purely funding‑led story.

Investor Backing & Capital Strength: Back‑to‑back late‑stage rounds in 2026, including a nine‑figure Series D followed quickly by a nine‑figure Series E with a stepped‑up valuation, suggest deep capital access and investor conviction. The rapid valuation increase provides additional financial flexibility for expansion.

Strategic Partnerships: Announcements in 2026 with organizations such as Atlantic Health and Priority Health indicate expanding distribution channels beyond direct employer sales. These relationships broaden market reach and embed the offering within health systems and plans.

Investor Backing & Capital Strength: Funding momentum is pronounced, with a $35M Series A (Mar 2025), $100M Series B (Sep 2025), and a $70M Series C (Sep 2026) bringing total capital to about $225M at a valuation above $500M. This pattern signals sustained investor appetite and a materially stronger capital position.

Strong Revenue Growth: Reporting indicates subscription revenue nearly quadrupled year over year to about $29M, while contracted revenue surpassed $60M. These figures point to rapid scaling of recurring and booked revenue.

Market Expansion: Commercial reach appears to be growing, with monitoring of roughly 40,000 residents across just over 500 senior-living communities and new deployments among named operators. Expanding partnerships and portfolio rollouts suggest a widening customer footprint.

Investor Backing & Capital Strength: A major 2026 investment of approximately $250 million from TPG’s Rise Fund is presented as fuel to scale the platform, expand the national network, and invest in technology. This level of capital support signals capacity to pursue multi-state implementations and product acceleration.

Market Expansion: Customer counts are reported to have risen from 570+ in 2023 to 825+ across all 50 states alongside new statewide wins in New Mexico and New York. Additional public-sector rollouts (e.g., TennCare and Delaware) and millions of monthly searches point to broader geographic and institutional reach.

Product Line Growth: Acquisitions such as Uno Health (2025) and Kiip (2024) expand capabilities from referrals toward digital eligibility, enrollment, and case management. This broadened scope supports a shift toward a more complete, full-stack social-care platform.

Market Expansion: Reported enrollments of roughly 250,000 in 2025 and a broker base exceeding 10,000 point to a rapidly widening operating footprint. AEP 2025 production metrics and tens of thousands of contracts processed further suggest the platform is scaling beyond its 2024 funding milestone.

Investor Backing & Capital Strength: A $25M Series B in January 2024, reportedly at a significant valuation step-up, underscores access to growth capital. Independent listings also record total funding in the high-$30Ms range, reinforcing external validation of capitalization.

Strong Hiring & Retention: Headcount reportedly expanded from around 40 to roughly 130 by 2025, and current postings include senior roles across revenue operations, engineering, product, and agent/customer experience. Active requisitions signal continued investment in growth infrastructure.

Strong Revenue Growth: Revenue is depicted as rising dramatically, including an increase from $3.6M in 2021 to $617.4M in 2024 and subsequent commentary citing a roughly $1B run rate.

Investor Backing & Capital Strength: Capital access appears robust, highlighted by a $150M Series D in 2026 at an approximately $3B valuation and total funding near $328M from prominent investors.

Market Expansion: Geographic and channel reach is expanding, with 26,000+ clinicians across all 50 states, 125+ insurance partners (including Medicare and Medicaid), and movement into employer and health‑system partnerships.

Investor Backing & Capital Strength: Investor backing is highlighted by seed and Series A rounds led by Accel and participation from notable angels, bringing total funding to roughly $19.7M. Feedback suggests this capital has supported team expansion and product development.

Market Expansion: Customer additions include fast-growing tech companies like Mintlify, Equals, and Braintrust, with accounts noting switches from legacy systems such as QuickBooks and NetSuite. Feedback suggests the company is extending its presence within the AI-native accounting niche for startups.

Innovation-Driven Growth: The platform combines an AI-native general ledger with managed services, continuous reconciliation, and tools like Prism for real-time financial exploration. Feedback suggests this differentiated product approach underpins traction among modern software companies.

Strong Revenue Growth: Bookings are reported to have grown 103% year over year in 2025, exiting at a roughly $1.1B annualized run rate, indicating rapid top-line momentum. Additional signals such as sustained wholesale growth reinforce that commercial scale is accelerating.

Healthy Cash Flow: Operations are described as cash-flow positive in 2025 while growth accelerated, suggesting improving financial sustainability alongside expansion. This combination points to scaling that is not purely subsidized by burn.

Investor Backing & Capital Strength: A $575M Series G at a $10.1B valuation underscores substantial access to capital and confidence from prominent investors. This financing is framed as enabling continued international expansion and hiring.

Market Expansion: Patient reach rose from 22M in 2022 to 25M in 2023 and 50M by January 2025, alongside new wins such as Sanford Health and multiple physician groups adopting the platform. Kora was also adopted by 10 provider organizations within its first year, reinforcing broader commercial uptake.

Product Line Growth: Cedar expanded from payments/billing into affordability, AI support, and the Kora AI agent in 2025–26, later broadening into the multi‑agent Kora Platform. Additional launches like Cedar Cover extended capabilities into Medicaid enrollment, renewals, and denials resolution.

Innovation-Driven Growth: AI‑driven workflows are central, with Kora handling roughly 400,000 patient calls in its first year and continued rollout of Cedar Intelligence in 2026. Recognition and ongoing AI feature releases signal a strategy centered on technology-led growth in healthcare financial workflows.

Market Expansion: Following the 2023 combination with Syntellis and the 2026 acquisition of c. myers, the company broadened beyond healthcare into higher education and financial institutions and cites 2,300+ organizations using StrataJazz and Axiom. These actions indicate a wider addressable market and a larger commercial footprint.

Innovation-Driven Growth: New offerings such as AI-driven Predictive Analytics and Financial Decision Intelligence, along with a Snowflake collaboration to scale data infrastructure, reflect sustained investment in product and technology. These initiatives signal an emphasis on scaling capabilities and deepening analytics.

Strong Market Position & Advantage: StrataJazz has been repeatedly recognized as No. 1/Best in KLAS for Business Decision Support, and the company is frequently described as a leader in its niche. A large installed base across thousands of providers reinforces its entrenched position in healthcare finance.

Investor Backing & Capital Strength: Recent financings include a $55M Series B led by Insight Partners and a prior $15M Series A, bringing total reported funding to roughly $77M. These capital events coincide with visible signals like active hiring and continued platform build-out.

Strong Revenue Growth: Growth is repeatedly described as 5x year-over-year since the Series A, alongside a 5x increase in valuation. Customer adoption reportedly expanded to 250+ CPG brands with $30B+ in retail sales planning flowing through the platform.

Product Line Growth: The offering has broadened from cash application and deductions into trade promotion management, sales forecasting, demand/supply planning, and analytics. Additions such as AI contract reading, auto‑disputes, and the Muffin Data acquisition indicate ongoing capability expansion.

Strong Revenue Growth: Estimates indicate annualized revenue rose sharply in 2024, with acceleration tied to GLP-1/obesity care. Evidence cites roughly $598M annualized revenue in 2024 versus about $360M in 2023.

Market Expansion: Recent launches and channel moves broadened reach, including nationwide availability of the Wegovy pill and a surge of new customers in early 2026. The platform reports helping millions of patients across nearly every U.S. county.

Strategic Partnerships: Direct integrations with major manufacturers (e.g., Novo Nordisk’s NovoCare for Wegovy and additional GLP-1 collaborations) position the company as a distribution/access channel. Novo Nordisk specifically described the company as part of its direct-to-patient expansion.

Strong Revenue Growth: Revenue is reported to have surpassed the $100 million annual mark with continued year-over-year gains. Feedback suggests momentum is reinforced by growth in newer verticals such as education and hospitality.

Market Expansion: The company extended its footprint from North America into the UK and Ireland and broadened placements beyond offices into campuses, hotels, gyms, warehouses, and other venues, while scaling to more than 6,000 customers. Feedback suggests international entry and vertical diversification are driving a larger installed base and usage milestones such as surpassing one billion single-use containers avoided.

Product Line Growth: The offering advanced from smart water coolers to a connected beverage platform, adding functional enhancements and a better-for-you soda line alongside new countertop hardware. Feedback suggests the expanded menu increases relevance across more locations and upsell potential within existing accounts.

Strong Revenue Growth: Revenue is described as sizable and growing rapidly, with independent reporting and credit analyses pointing to continued double‑digit expansion. ARR and ACV are characterized as increasing consistently since 2022.

Customer Loyalty & Retention: Retention is depicted as very high, with consistent expansion within existing accounts that supports sustained recurring revenue growth. Commentary highlights strong share‑of‑wallet gains and durable renewals across healthcare customers.

Product Line Growth: The portfolio has broadened through repeated acquisitions (e.g., SecureLink, Verosint) and new capabilities such as passwordless authentication and agentic identity management. These moves signal active investment to expand addressable use cases and deepen the platform.

Market Expansion: Reach is described as nationwide, with thousands of imaging partners and access extended through employer and health‑plan channels to a large member base. This breadth indicates rapid scaling from an early-stage footprint.

Investor Backing & Capital Strength: Capital raises include a sizable Series A led by established investors, signaling confidence in continued scaling. Funding momentum accompanies ongoing hiring and expanded employer and health‑plan integrations.

Strong Revenue Growth: Investor commentary cites revenue increasing more than tenfold since an earlier investment, alongside company claims of very rapid growth. Together these signals point to accelerating topline momentum, even as precise figures remain undisclosed.

Strong Revenue Growth: Operating revenue increased meaningfully year over year while capacity also rose, signaling robust top-line momentum in tandem with expanding operations. Feedback suggests this growth has been sustained across consecutive fiscal periods.

Market Expansion: The network has broadened to 32 destinations with cumulative passengers surpassing 25 million, alongside added international routes and higher departures. These developments indicate widening reach and growing traffic throughput.

Future-Ready Strategy: Management outlines continued capacity growth over the next several years, supported by a large Boeing 737 MAX order pipeline. This long-horizon fleet plan underpins ongoing scale-up ambitions.